Aayushi Pratap

New York, United States

Associate Editor at C&EN

Business Reporter @C&EN Formerly@Forbes@GenomeWeb@Hindustan Times ||@ColumbiaJourn @PharmaCorrespondent @eurekalert fellow||

Featured in: Favicon

genomeweb.com Favicon

forbes.com Favicon

hindustantimes.com Favicon

sciencenews.org Favicon

forbes.com.br Favicon

forbesjapan.com Favicon

forbes.es

forbesmiddleeast.com Favicon

realclearscience.com Favicon

endpts.com + 9 more

Articles

Colorado start-up launches to improve drug discovery chemistry

2 weeks ago | cen.acs.org | Aayushi Pratap

A new company has entered the drug discovery space with what it calls a "chemistry-first" platform. Colorado-based Cime Therapeutics has emerged from stealth with $2.1 million in preseed financing to advance its method for efficiently synthesizing and screening molecules that could become oncology drugs.
Disheartened by funding cuts, international students look beyond the US

2 weeks ago | cen.acs.org | Aayushi Pratap

Credit: Madeline Monroe/C&ENFor chemistry students across the globe, coming to the US to pursue graduate education is often the dream. Ample funding, access to cutting-edge research facilities, and the ease of transitioning into industry from academia have attracted international talent to the US for decades. But for many, that dream has suddenly been upended. Research funding cuts by the second Donald J.
Disheartened by funding cuts, international students look beyond the US

3 weeks ago | cen.acs.org | Aayushi Pratap

For chemistry students across the globe, coming to the US to pursue graduate education is often the dream. Ample funding, access to cutting-edge research facilities, and the ease of transitioning into industry from academia have attracted international talent to the US for decades. But for many, that dream has suddenly been upended. Research funding cuts by the second Donald J.
Boston AI start-up raises $200 million

1 month ago | cen.acs.org | Aayushi Pratap

After 2 years in stealth, a Cambridge, Massachusetts-based start-up has emerged with plans to conduct science in automated laboratories that run on a special version of artificial intelligence. Lila Sciences has secured $200 million in seed funding from Flagship Pioneering, which incubated the company, and General Catalyst, March Capital, Ark Venture Fund, and others.
Can tiny lab-grown plants solve a big vaccine problem?

2 months ago | cen.acs.org | Aayushi Pratap

Chile is home to the rare soapbark tree, known in the scientific community as Quillaja saponaria. These evergreens, which can stand 15 to 20 m tall and take a quarter of a century to mature, are by no means ordinary. All their organs-but especially the bark-contain soapy compounds called saponins that have been used in skin-care creams, beverages, detergents, and cough and cold remedies for over a century.
AI drug discovery start-up Manas secures $24.6 million in funding

2 months ago | cen.acs.org | Aayushi Pratap

By Manas AI, an artificial intelligence drug discovery venture cofounded by the LinkedIn founder Reid Hoffman and the cancer researcher Siddhartha Mukherjee, has raised $24.6 million in seed funding. The start-up says it will use its AI platform to screen vast chemical libraries and find drug candidates for treating cancers, autoimmune diseases, and rare conditions. Manas says it has partnered with Microsoft to access that firm's Azure cloud computing platform.
The ‘compuchem’-AI showdown

2 months ago | pubs.acs.org | Aayushi Pratap

Monday, January 27, 2025 Please be aware that pubs.acs.org is undergoing maintenance on Saturday, November 16, at 6 p.m. EDT that may have an impact on your experience. During this time, you may not be able to access certain features like login, purchasing single articles, saving searches or running existing saved searches, modifying your e-Alert preferences, or accessing Librarian administrative functions. We appreciate your patience as we continue to improve the ACS Publications platform.
Lacamas buys Grace plant in Oregon

Jan 23, 2025 | cen.acs.org | Aayushi Pratap

By Lacamas Laboratories, a Portland, Oregon-based specialty chemical maker, has acquired a fine chemical facility in Albany, Oregon, from W. R. Grace. The company owned the plant, which employs more than 20 people, since 2010. Lacamas's main businesses include manufacturing pharmaceutical raw materials and defense chemicals for the military. It was awarded an $86 million contract by the US Department of Defense last year to set up production of chemicals used to make munitions.
Indian drug services companies pull in cash

Jan 13, 2025 | cen.acs.org | Aayushi Pratap

Indian firms want to rebrand the country as the next big destination for Western pharmaceutical and biotechnology companies looking to outsource drug development. In recent months, several Indian contract development and manufacturing organizations (CDMOs) have gone public or raised venture-backed funds in an effort to realize this goal. Aragen Life Sciences announced on Jan.
AI will be everywhere in chemistry

Jan 10, 2025 | cen.acs.org | Aayushi Pratap

Artificial Intelligence is the hottest ticket in pretty much every industry, and that includes chemistry. While some chemists are using the tool to discover new drugs, others are deploying it to generate ecofriendly materials or to make manufacturing processes more efficient and sustainable. C&EN reached out to the leaders of five companies working at the intersection of AI and chemistry to gather their views on the field's possible defining moments in 2025.